GRIN2A and neurodegenerative disease: Chazot et al. in 2004 [39] further emphasized the significance of targeting specific NR2 isoform(s) expressed in the receptor, i.e., GluN2A and GluN2B subunit-containing NMDA receptors, in conditions such as ischemic stroke and neurodegenerative diseases.